However,despite their therapeutic potential, only a few PDE4 inhibitors havereceived market approval, largely due to their narrow therapeuticwindow and dose-limiting adverse effects such as emesis, which restricttheir clinical utility.8 As an alternativeapproach, targeting another cAMP-specific phosphodiesterase, PDE7,has gained attention, given its expression in immune and pro-inflammatorycells and its involvement in inflammatory and neurodegenerative diseases. This evidence concerns the gene PDE7A and neurodegenerative disease.